Gates Package, pp.469-472 · gates:email:00378
Page text: p.469, p.470, p.471, p.472 · original PDF
- Date
- — (unknown precision)
- Type
- email · email
- sender
- Robert Hiouail Nin. Gov Eiss
exchange.nih.gov>, "Brewinski Isaacs, Maggie (NIH/NICHD) [E]"
)mail.nih.gov>, "Freund, Lisa (NIH/NICHD)
[E]"
)mail.nih.gov>, "Hazra, Rohan (NIH/NICHD) [E]"
mail.nih.gov>,
"Tlekis, John
(NIH/NICHD) [E]" [@mail.nih.gov>, "Krotoski, Danuta (NIH/NICHD)
[E]"
mail. nih.gov>, "Lee, Sonia
(CHD) [E]" BE nit cov>,
"Moss, Stuart (NIH/NICHD)
[E]"
)mail.nih.gov>, "Newcomer, Susan
(NIH/NICHD) [E]"
exchange.nih.gov>, "Raiten, Daniel (NIH/NICHD) [E]"
)mail. nih.gov>, "Reddy, Uma
TCHD) [E]" BEB omnait nin. gov>,
"Signore, Caroline (NIH/NICHD) [E]"
)mail.nih.gov>, "Barry, Clifton
(NIWNIADD) [E]" [oniaid.nib.gov>, "Boyce, Jim
TAID) [E]"
jnih.gov>,
"Cassels, Fred (NIH/NIAID) [E]"
niaid.nih.gov>, "Datta,
Sandi
TAID) [E]" BEB oniaicnin gov>, "Green, Kim
(NIH/NIAID) [E]"
niaid.nih.gov>, "Hall, Lee (NIH/NIAID)
[E]"
niaid.nih.gov>,
"Koso-Thomas, Marion
(NIH/NICHD) [E]" pe eee "Kurilla, Michael
(NIW/NIAID) [E]" Mo vicidatanon "Lacourciere, Karen (NIH/NIAID) [E]"
niaid.nih.gov>, "Lambert, Linda (NIH/NIAID) [E]"
\niaid.nih.gov>, "Ledgerwood, Julie (NIH/NIAID) [E]"
niaid.nih.gov>, "Marovich, Mary (NIH/NIAID) [E]"
mnih.gov>, "Marston, Hilary (NIH/NIAID) [E]"
'ih.gov>, "Mascola, John
(NIH/VRC) [E]"
mail.nih.gov>,
"Zwerski, Sheryl
)) [E]" WIM wisch goo "Kreimer, Aimee
(NIH/NCD [E]" Rone ane "Schiffman, Mark (NIH/NCI) [E]"
exchange.nih.gov>, "Pringle, Beverly (NIH/NIMH-
"
mail.nih.gov>, "Buckley, Shu
(NIH/NIMH) [E]"
\nih.gov>,
"Rosenthal, Josh P.
(NIH/FIC) [E]"
)ficod.fic.nih.gov>, "Gottlieb, Michael
(ENTE)
[T]" --fnih.org>, "Kurilla, Michael (NIH/NIAID) [E]"
idee "Rao, Malla (NIH/NIAID) [E]"
niaid.nih.gov>,
"Costero-Saint Denis, Adriana
TAID) [E]"
niaid.nih.gov>, "Deye,
Greg
(NIH/NIAID) [E]" Oni oc "Mcgugan, Glen (NIH/NIAID) [E]"
em
"Handley, Gray (NIH/NIAID) [E]"
niaid.nih.gov>
Ce: "Kline, Lydia (NIH/FIC) [C]" [@nih.gov>, "Weymouth, Kristen (NIH/FIC) [E]"
mail.nih.gov>, "Wan. ane: iG) [e]" BE vit cov>,
"Officer, Jackie (NIH/FIC) [E]"
nih.gov>
Subject: NIH-Gates Foundation Workshop, July 8: Agenda and list of participants
Date: Wed, 01 Jul 2015 17:08:29 -0400
Importance: Normal
Attachments: BMGF-NIH_Second_Annual_
Meeting
(7.1).docx; NIHBill_& Melinda_Gates_Foundation_Participant_List_July_Workshop_7.1.docx
Dear Colleagues,
We look forward to your participation the NIH-Bill & Melinda Gates Foundation Workshop next week _| attach the
current agenda and list of Gates Foundation and NIH participants. There may be a few late confirmations and/or needed
corrections. A final list of participants will be available at the meeting I also will send on any pre-reads suggested by any
of the working group co-chairs.
Please don't hesitate to contact me with and questions
_If needed, my cell is
TE -'--
Best regards
Bill & Melinda Gates Foundation-NIH Second Annual Consultative Workshop
July 8, 2015
John Edward Porter Neuroscience Research Center (Building 35A)
NIH Campus, Bethesda, Maryland
8:30 AM - 8:40 AM
Welcome -- Francis Collins, Trevor Mundel
8:40 AM - 9:30 AM
Drug Repurposing and Global Health: Accelerating the Pace.
Co-Moderators: Dr. Chris Austin, NCATS; Dr. Trevor Mundel, BMGF
The session will focus on innovations in early and late stage drug repurposing, and relevance
to priority therapeutics for global health. Priority topics include:
•
accessing data & compounds from innovator firms
•
corporate incentives and models of collaboration
•
creative IP management
•
crowdsourcing and clearinghouses
•
support for Phase IIb and III
9:30 AM - 10:30 AM
Research Preparedness and Lessons Learned from the Ebola Outbreak
Co-moderators: Dr Cliff Lane, NIAID; Alan Magill, BMGF
The session will take stock of the challenges encountered in responding to microbial
outbreaks, based on the recent experience with Ebola epidemic. The aim is to understand
generalizable lessons from this response, and explore ways to most effectively address
future outbreaks. Priority topics include:
•
clinical trial design
•
implementing clinical trials
•
developing protocols and guidance for research studies in advance
•
sharing of specimens and data, and access to specialized reagents
•
community engagement
•
coordination and real-time, open sharing of information across diverse disciplines
•
challenges of implementing rapid funding
10:30 AM - 10:45 AM
Coffee break
se Priorities